Brivaracetam Tablets IP 50mg AQB – BC offers an advanced therapeutic approach for the treatment of partial-onset seizures in patients with epilepsy. Each film-coated tablet contains Brivaracetam 50 mg, a highly selective antiepileptic agent that binds with strong affinity to synaptic vesicle protein 2A (SV2A). This targeted mechanism helps stabilize neural activity, providing fast onset and sustained seizure control with minimal drug interactions.
Designed for both adults and adolescents (16 years and above), this formulation is well-tolerated and ideal for long-term adjunctive therapy. With a convenient tablet form and clear dosing, it enhances treatment adherence while minimizing central nervous system side effects commonly associated with traditional AEDs.
Key Benefits:
- Effective control of partial-onset seizures
- Rapid onset of action with high selectivity
- Lower potential for drug interactions
- Suitable for use alongside other antiepileptic medications
- Easy-to-administer film-coated tablets
Indications: Partial-onset seizures associated with epilepsy (monotherapy or adjunctive therapy)
Composition: Each film-coated tablet contains: Brivaracetam IP – 50 mg
Colour: Red oxide of Iron
Dosage: As directed by the physician.
Storage: Store in a cool, dry & dark place, at a temperature not exceeding 25°C. Protect from light and moisture.
Pack Size: 10×10 Tablets (Alu-Alu Blister)
Ram –
helps control partial-onset seizures by targeting synaptic vesicle protein 2A (SV2A) in the brain.